Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stage I Prostate Adenocarcinoma 1Sarcoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Melanoma 1Hemangiosarcoma 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1

Interventions

Imatinib Mesylate 32regorafenib 9Sunitinib 9Laparoscopy 5Dasatinib 4Blood Specimen Collection 4pazopanib 3nilotinib 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Paclitaxel 3Observation 3spartalizumab 2ripretinib 2envafolimab 2binimetinib 2apatinib 2Temozolomide 2Neoadjuvant Therapy 2Ipilimumab 2Gemcitabine 2Docetaxel 2Cisplatin 2Carboplatin 2Capecitabine 2CTLA-4 Antigen 2Biopsy, Fine-Needle 2Biopsy 25-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastrointestinal Stromal Tumors × pexidartinib × Clear all
NCT03158103 2021-04-30

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
3 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡